Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence

Table 2 Randomized double-blinded placebo controlled trials on house dust mite sublingual Immunotherapy for the treatment of allergic rhinitis in children

Ref.	Year	Mean age (yr)	No. of patients	Product	Efficacy parameters	Duration	Statisticalsignificance	Other observation
Marcucci et al[33,34]	2005	4-15	24	Aqueous solution (ALK-Abello’)	Symptoms score	1 yr	NS	A significant difference was recorded in the last trimester of the year; the study was carried on after the first year in open way
Tseng et al[31]	2008	6-18	59	Staloral (Stallergenes)	Symptoms score	6 mo	NS	In treated group a slight improvement was recorded. Specific IgG4 and IgG4/IgE significantly increased in SLIT group
Yonekura et al[35]	2010	7-15	31	Extract of house dust mite (Torii Pharmaceutical)	Symptom score	40 wk	P < 0.05	The improvement in SLIT group increased progressively according to the duration of the therapy
de Bot et al[36]	2012	6-18	251	Oralgen House Dust Mite (Oralgen Mijten)	Symptom score	2 yr	NS	Study population was recruited in primary care setting
Aydogan etal[41]	2013	5-10	22	Staloral (Stallergenes)	Medication and symptom score	12 mo	NS	-

SLIT: Sublingual Immunotherapy; NS: Not significant.